Sign In
Buy BMY
$56.60
+1.88 (+3.44%)
At Close: Jun 04, 2026
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #COBENFY--U.S. FDA Approves Bristol Myers Squibb's COBENFY, a First-In-Class Muscarinic Agonist for the Treatment of Schizophrenia in Adults.
Bristol-Myers Squibb's Novel Schizophrenia Drug Wins FDA Approval; BMY Stock Signals Breakout
07:35pm, Thursday, 26'th Sep 2024
Bristol-Myers Squibb won FDA approval for its novel schizophrenia drug, Cobenfy. BMY stock rose late, signaling a breakout Friday.
US FDA approves Bristol Myers' schizophrenia drug
06:50pm, Thursday, 26'th Sep 2024
The U.S. health regulator approved Bristol Myers Squibb's schizophrenia drug on Thursday, providing patients with a treatment option that reduces symptoms of the mental disorder without common side ef
FDA approves Bristol Myers Squibb's schizophrenia drug, the first new type of treatment in decades
06:46pm, Thursday, 26'th Sep 2024
The Food and Drug Administration approved Bristol Myers Squibb's highly anticipated schizophrenia drug, the first novel type of treatment for the debilitating, chronic mental disorder in more than sev
TSVT, BMY Discontinue Enrollment in Late-stage Abecma Study
10:10am, Thursday, 26'th Sep 2024
2seventy bio and partner BMY decide to stop enrollment in the late-stage study on Abecma due to growth in the newly diagnosed multiple myeloma treatment space.
Bristol Myers Squibb Vs. AbbVie Stock
07:00am, Thursday, 26'th Sep 2024
Given its better valuation, we believe that Bristol Myers Squibb stock (NYSE: BMY) is currently a better pick than its peer – AbbVie stock . BMY stock trades at a much lower multiple of 2.2x revenue
Bristol Myers-2seventy Bio Halt Phase 3 Trial For Abecma In Newly Diagnosed Myeloma Patients, Speeds Path To Profitability
11:56am, Wednesday, 25'th Sep 2024
2seventy bio, Inc TSVT and its partner Bristol Myers Squibb & Co BMY, will discontinue enrollment in its ongoing Phase 3 KarMMa-9 study of Abecma (idecabtagene vicleucel; ide-cel) with lenalidomide
Raise Cash And Sell Trash
08:05am, Saturday, 21'st Sep 2024
As a dividend growth investor focused on income, I recommend raising cash and selling lower-quality stocks due to potential recession risks. Historical data shows that rate cuts often precede recessio
5 Incredible Healthcare High-Yield Blue-Chip Bargain Buys For 2025
07:00am, Thursday, 19'th Sep 2024
Healthcare is undervalued despite being the top sector for earnings growth, making it an attractive investment with solid fundamentals and the potential for explosive returns in 2025. Investing in hea
New Long-Term Zeposia (ozanimod) Data Demonstrate Durable Efficacy and Consistent Safety in Relapsing Forms of Multiple Sclerosis
06:59am, Wednesday, 18'th Sep 2024
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #DAYBREAK--New Long-Term Zeposia (ozanimod) Data Demonstrate Durable Efficacy and Consistent Safety in Relapsing Forms of Multiple Sclerosis.
Bristol Myers Squibb (BMY) Stock Dips While Market Gains: Key Facts
06:51pm, Tuesday, 17'th Sep 2024
Bristol Myers Squibb (BMY) closed at $49.49 in the latest trading session, marking a -1% move from the prior day.
3 Wide Moat Stocks to Buy for an Economic Slowdown
11:40am, Tuesday, 17'th Sep 2024
#Morningstar #MicrosoftStock #StockInvesting These undervalued stocks have defensive qualities that make them attractive in today's market. 00:00 Introduction 00:43 Bristol Myers Squibb BMY 01:22 C
Bristol Myers Squibb Company (BMY) Is a Trending Stock: Facts to Know Before Betting on It
10:06am, Monday, 16'th Sep 2024
Bristol Myers (BMY) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Radioactive cancer technology: New billion dollar opportunity?
09:33am, Monday, 16'th Sep 2024
CNBC's Angelica Peebles joins 'Squawk Box' with the latest news.
3 High-Yield Dividend Stocks Down by More Than 39% to Buy Now and Hold at Least a Decade
05:23am, Monday, 16'th Sep 2024
Brookfield Renewable Partners offers a juicy dividend yield that could rise steadily along with electricity demand. Royalty Pharma's portfolio of pharmaceutical products is growing by leaps and bounds
